Interview with Hyun Ho Jung, CEO, Medy-Tox
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
Address: Ochang Science Industry Complex 641-4 Gak-ri, Ochang-eup, Chungbuk 363-883, Republic of Korea
Tel: +82-43-217-1555
Web: http://www.medy-tox.co.kr/
Medy-Tox is a biotech venture company established in 2000 with a goal of developing botulinum toxin-based injections. Through the hard work and dedication of our employees, MEDITOXIN (‘NEURONOX, in the overseas market) was developed in 2006. MEdy -Tox’s products are very popular with not only domestic customers but also overseas customers and the demand for them is rapidly increasing annually. Medy Tox aims to become the best bio pharmaceutical manufacturer in Republic of Korea and to compete with the world’s biotech venture company. Medy Tox’s genuine efforts on next-generation botulinum products have been paying off one by one. Meditox will be able to provide our customers with a different product every year.
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion…
Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their…
Industry players – from Big Pharma giants to small local startups – are bringing new, innovative solutions to market in Korea in order to try and solve the country’s diabetes…
The nation of South Korea has overtaken many of its regional counterparts to boast a highly impressive biosimilars pipeline. Here, key stakeholders in Korean biologics and biosimilars explain how. …
ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its parent company’s…
CEO of the Life Science division of LG – one of Korea most recognized global brands – Dr Jeewoong Son has spent much of his career gathering the knowhow to…
One of the indisputable economic success stories of the last half-century, South Korea now stands as the world’s 11th largest economy, with a reputation for industrial excellence and innovation. As…
The Korean cosmetics market is now the 8th largest in the world, with 2.9 percent of the global market share, capitalising on the global rise in interest for Korean culture,…
SK Plasma is a blood plasma company that was spun off from SK Chemicals in 2015. Its CEO, Yun Ho Kim, offers his insights into the company’s vision to establish…
See our Cookie Privacy Policy Here
